[ad_1]
However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more
A one-step RT-PCR test for the detection of the SARS-CoV-2 coronavirus was developed by a Hungarian-owned molecular diagnostics company, Omixon Biocomputing Kft., Present on the international market, which received the Conformité Européenne (CE ) European For a product called AzureSeq. As company communication emphasizes:
A revolutionary new laboratory process has been used to detect viral RNA, so it is not necessary to extract it from the sample as a first step.
“The classic PCR test is based on the detection of the viral RNA extracted from the sample. RNA extraction also requires an expensive and time-consuming process that takes several hours, a reagent, and a dedicated professional. Additionally, reagent companies are often unable to deliver adequate quantities or on time. That is why there is a great need for a test that does not require RNA extraction, but can be detected directly from the sample taken, ”said Dr. Barna Vásárhelyi, director of the Institute of Laboratory Medicine at the University from Semmelweis, participated in the preliminary examination of the device. As you said, the newly developed one-step direct RT-PCR test was tested and the results obtained were completely identical to the results of classic PCR tests.
Rector Dr. Béla Merkely emphasized: The tests carried out with the new test developed in Hungary give faster results, bring together the capacity of fewer specialists and are expected to be more cost-effective, so the University of Semmelweis will use them in increasing quantities in the future.
The Hungarian company AzureSeq was developed in cooperation with SeqOnce Biosciences, California, and has exclusive distribution rights in Europe, the Middle East and Africa.
Cover Source: Getty Images
[ad_2]
